Leukemia
Journal
Overview
publication venue for
-
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
2019
-
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
2019
-
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
2019
-
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
2019
-
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia
2019
-
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
2019
-
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.
32:547-549.
2018
-
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
32:353-363.
2018
-
High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.
32:419-428.
2018
-
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
2018
-
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
32:83-91.
2018
-
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
2018
-
CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.
31:2254-2257.
2017
-
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.
31:1882-1893.
2017
-
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
31:1368-1374.
2017
-
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
31:1391-1397.
2017
-
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
2017
-
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients.
31:970-973.
2017
-
Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
31:585-592.
2017
-
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
31:625-636.
2017
-
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
31:393-402.
2017
-
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen
2017
-
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
31:2726-2731.
2017
-
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
31:241-244.
2017
-
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
31:115-122.
2017
-
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
31:136-142.
2017
-
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.
31:151-158.
2017
-
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
30:2402-2405.
2016
-
Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.
30:1116-25.
2016
-
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.
30:1133-42.
2016
-
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
30:649-57.
2016
-
EBV-miR-BHRF1-2 targets PRDM1/Blimp1: Potential role in EBV lymphomagenesis.
30:594-604.
2016
-
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
30:190-9.
2016
-
FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice.
30:1-13.
2016
-
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche
2015
-
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
29:2238-47.
2015
-
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
29:1832-8.
2015
-
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.
29:1267-78.
2015
-
Immunosuppressive therapy of LGL leukemia: Prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).
29:886-94.
2015
-
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
29:1390-401.
2015
-
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.
29:137-44.
2015
-
Functional characterization of BTK C481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors.
29:895-900.
2015
-
Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
29:895-900.
2015
-
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
29:415-22.
2015
-
IL10 receptor is a novel therapeutic target in DLBCLs.
29:1684-94.
2015
-
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
29:1290-300.
2015
-
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
29:1981-92.
2015
-
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
29:847-57.
2015
-
Risk of myeloid neoplasms after solid organ transplantation.
28:2317-23.
2014
-
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
28:649-57.
2014
-
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
28:649.
2014
-
Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
28:1698-704.
2014
-
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: Implications for epigenetic therapy.
28:147-54.
2014
-
High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): Cytogenetic features, clinical characteristics and outcome.
28:1511-8.
2014
-
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031.
28:1467-71.
2014
-
Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.
28:174-8.
2014
-
Racial disparities in the prevalence of monoclonal gammopathies: A population-based study of 12 482 persons from the national health and nutritional examination survey.
28:1537-42.
2014
-
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.
27:2341-50.
2013
-
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.
27:2177-86.
2013
-
AKT is a therapeutic target in myeloproliferative neoplasms.
27:1882-90.
2013
-
Toll-like receptor alterations in myelodysplastic syndrome.
27:1832-40.
2013
-
Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety.
27:1707-14.
2013
-
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis.
27:1310-5.
2013
-
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.
27:823-8.
2013
-
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
27:852-60.
2013
-
MiR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
27:344-52.
2013
-
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
27:220-5.
2013
-
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
27:66-74.
2013
-
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
27:208-12.
2013
-
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study.
26:2103-13.
2012
-
Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.
26:1771-8.
2012
-
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: Ontogenetic implications.
26:1638-46.
2012
-
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
26:893-901.
2012
-
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.
26:481-9.
2012
-
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
25:281-9.
2011
-
Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.
25:145-52.
2011
-
PHF6 mutations in adult acute myeloid leukemia.
25:130-4.
2011
-
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
24:1302-9.
2010
-
A multi-center phase i study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
23:2259-64.
2009
-
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
23:1605-13.
2009
-
Monoclonal antibodies against IREM-1: Potential for targeted therapy of AML.
23:1587-97.
2009
-
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
23:2147-52.
2009
-
Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates.
23:900-4.
2009
-
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
23:905-11.
2009
-
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
23:1139-51.
2009
-
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
23:574-80.
2009
-
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.
23:287-91.
2009
-
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
22:2176-83.
2008
-
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
22:1707-11.
2008
-
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
22:1917-24.
2008
-
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: Molecular basis for antitumor activity and drug resistance of dasatinib.
22:1755-66.
2008
-
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
22:1200-6.
2008
-
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.
22:1139-43.
2008
-
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
21:1658-68.
2007
-
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: Towards new standards for gene expression measurements.
21:1481-7.
2007
-
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
21:739-46.
2007
-
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
21:489-93.
2007
-
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
21:169-74.
2007
-
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
20:2025-33.
2006
-
Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2.
20:1790-9.
2006
-
Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells.
20:979-86.
2006
-
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
20:952-7.
2006
-
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
20:212-7.
2006
-
Results of a phase I/II trial adding carmustine (300mg/m2) to melphalan (200mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
20:345-9.
2006
-
Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide [3].
19:873-5.
2005
-
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
19:39-43.
2005
-
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
19:27-30.
2005
-
Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998).
18:1605-10.
2004
-
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
18:1352-6.
2004
-
Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: A report from the Children's Cancer Group.
18:939-47.
2004
-
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study.
18:309-15.
2004
-
Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: Possible mediation of hypoxia-inducible factor-1α.
17:2065-73.
2003
-
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
17:1967-72.
2003
-
Low expression of the myeloid differentiation antigens CD65s, a feature of poorly differentiated AML in older adults: Study of 711 patients enrolled in ECOG trials.
17:1544-50.
2003
-
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
17:481-7.
2003
-
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
17:604-11.
2003
-
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
17:314-8.
2003
-
Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.
16:1673-9.
2002
-
Long-term follow-up of short intensive chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin lymphoma: A children's cancer group report.
16:594-600.
2002
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
16:1627-36.
2002
-
Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): No evidence for intrinsic growth advantage of PNH clones.
16:2243-8.
2002
-
Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.
16:1484-9.
2002
-
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
16:60-6.
2002
-
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
16:60-6.
2002
-
Retinoic acid syndrome: A problem of the past?.
16:160-1.
2002
-
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
15:963-70.
2001
-
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission.
15:757-63.
2001
-
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stems cells.
14:1777-84.
2000
-
A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes.
14:1614-20.
2000
-
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
14:1577-82.
2000
-
Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia.
14:1345-8.
2000
-
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4.
14:292-8.
2000
-
Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21.
13:1534-8.
1999
-
Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid.
13:1258-65.
1999
-
Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis.
13:1243-53.
1999
-
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.
12:865-8.
1998
-
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission.
11:1533-9.
1997
-
Rapid induction of B-cell lymphomas by avian leukosis virus.
11:179-82.
1997
-
Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia.
11:886-9.
1997
-
Studies of decitabine with allogeneic progenitor cell transplantation.
11:S32-4.
1997
-
c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells.
10:1436-42.
1996
-
Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions.
10:1237-40.
1996
-
Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
10:321-6.
1996
-
c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
10:229-37.
1996
-
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
10:32-9.
1996
-
A pilot study of the biologic and therapeutic effects of granulocyte colonystimulating factor (filgrastim) in patients with acute myelogenous leukemia.
9:1799-804.
1995
-
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
9:1631-7.
1995
-
Familial acute myeloid leukemia and DiGuglielmo syndrome.
9:1091-4.
1995
-
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: Long-term follow-up results of study by Cancer and Leukemia Group B.
9:1116-20.
1995
-
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
9:244-8.
1995
-
Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia.
9:1653-60.
1995
-
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience.
8:S33-7.
1994
-
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
8:1290-3.
1994
-
Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines.
8:1191-6.
1994
-
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience.
8:929-33.
1994
-
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
8:749-57.
1994
-
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
8:758-67.
1994
-
A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.
8:688-93.
1994
-
Phase I-II trial of high dose ARA-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.
8:531-4.
1994
-
In vitro establishment of AIDS-related lymphoma cell lines: Phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection.
7:1621-9.
1993
-
Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL.
7:1020-5.
1993
-
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
7:832-7.
1993
-
Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia.
7:758-9.
1993
-
Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.
7:1000-4.
1993
-
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
6:1189-91.
1992
-
Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
6:1185-8.
1992
-
Diffuse large cell lymphoma. Prognostic factors with treatment.
5:32-7.
1991
-
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase) - a pilot study.
5:991-8.
1991
-
Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
5:386-91.
1991
-
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia.
5:540-7.
1991
-
Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
5:712-4.
1991
-
Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.
4:625-30.
1990
-
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL).
4:177-83.
1990
-
Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
3:446-52.
1989
-
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: Results of the L-16M protocol.
3:115-21.
1989
-
Establishment and characterization of two human myeloma cell lines secreting kappa light chains.
3:729-35.
1989
-
Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia.
3:440-5.
1989
-
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.
3:339-48.
1989
-
Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies.
2:19-26.
1988
-
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.
2:642-7.
1988
-
Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2.
1:305-7.
1987
-
Juvenile chronic myeloid leukemia: Therapeutic insights.
1:730-3.
1987
-
Clonal chromosomal abnormalities in CD34+/CD-38 hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
24:1525-8.
2010
-
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis [16].
20:2067-2070.
2006
-
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma [4].
17:2238-40.
2003
-
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571 [3].
15:1795-7.
2001
-
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
15:1317-25.
2001
-
Extensive bone marrow necrosis associated with multiple myeloma [3].
13:2118-20.
1999
-
Discordant erythropoiesis in CML (multiple letters) [3].
12:444-5.
1998
-
Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA) [1].
11:170.
1997
-
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
2009
-
Chronic myeloid leukemia - Some topical issues.
21:1347-52.
2007
-
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
2019
-
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial
2017
-
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
2016
-
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia
2016
-
Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia
2015
-
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
2015
-
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis
2015
-
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma
2015
-
Bone marrow angiogenesis in myeloma and its precursor disease: A prospective clinical trial
2014
-
Acceleration of Bcr-Abl + leukemia induced by deletion of JAK2
2014
-
Improved long-term survival in multiple myeloma up to the age of 80 years
2014
-
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: Results from children's oncology group study AALL0031
2014
-
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
2014
-
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: Incidence and prognostic significance
2013
-
Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma
2012
-
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
2011
-
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
2011
-
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration
2010
-
Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines
2010
-
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia
2009
-
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
2009
-
Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma
2009
-
BIC is processed efficiently to microRNA-155 in Burkitt lymphoma cells
2008
-
Systematic genomic screen for tyrosine kinase mutations in CLL
2008
-
A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease
2008
-
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
2008
-
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation
2008
-
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients
2008
-
JAK2 Mutations are present in all cases of polycythemia vera
2008
-
The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma
2008
-
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment [6]
2008
-
A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias [10]
2007
-
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies [4]
2006
-
NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis [4]
2006
-
Ph-positive and -negative myeloproliferative syndromes may co-exist [1]
2004
-
Thalidomide therapy induces response in relapsed mantle cell lymphoma [7]
2003
-
Clinical activity of arsenic trioxide in Burkitt-like lymphoma [3]
2003
-
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells
2016
-
Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both
2016
-
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
2015
-
Clonal evolution in hematological malignancies and therapeutic implications
2014
-
Inherited genetic susceptibility to multiple myeloma
2014
-
MYD88 and beyond: Novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia
2014
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
2014
-
Update on second primary malignancies in multiple myeloma: A focused review
2014
-
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
2013
-
The ASXL-BAP1 axis: New factors in myelopoiesis, cancer and epigenetics
2013
-
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
2012
-
Management of treatment-emergent peripheral neuropathy in multiple myeloma
2012
-
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma
2011
-
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
2010
-
Monoclonal B-cell lymphocytosis (MBL): Biology, natural history and clinical management
2010
-
International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
2009
-
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
2009
-
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: Support for genetic factors in pathogenesis
2009
-
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
2009
-
JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science
2008
-
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
2008
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
2008
-
Predicting the effect of transcription therapy in hematologic malignancies
2005
-
Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies
2003
-
Elitek™-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002
2003
-
Sphingosine 1-phosphate as a therapeutic agent
2002
-
Therapy of acute promyelocytic leukemia: All-trans retinoic acid and beyond
1998
-
New understanding of the pathogenesis of CML: A prototype of early neoplasia
1997
-
Differentiating therapy in acute myeloid leukemia
1996
-
Differentiating therapy in acute myeloid leukemia
1996
-
Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia
1996
-
Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment
1993
-
Basophilic differentiation in acute promyelocytic leukemia
1993
-
Pediatric leukemia/lymphoma with t(8;14)(q24;q11)
1992
-
Acute lymphoblastic leukemia: Present and future
1992
-
Blastic phase of chronic myeloid leukemia (blCML): A proposal for standardization of diagnostic and response criteria
1990
-
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease
1989
-
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
2005
-
Spotlight on acute promyelocytic leukemia: Controversies and challenges
2002
-
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
2019
-
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma
2019
-
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
2019
-
Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis
2009
-
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? [15]
2006
-
Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera [1]
2003
Identity
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)